Hydrocortisone tablets (50277)
Hydrocortisone tablets (50277)

The following Competition guidance note provides comprehensive and up to date legal information covering:

  • Hydrocortisone tablets (50277)
  • Case facts
  • Timeline
  • Commentary
  • Related cases

CASE HUB

See further, timeline, commentary and related cases.

Case facts

Outline CMA Article 101 TFEU/Chapter I and Article 102 TFEU/Chapter II investigation into alleged anti-competitive agreements and abuses of dominance incentivising delayed entry into the market and excessive and unfair prices for hydrocortisone tablets.

Latest developments On 12 February 2020, the CMA issued a supplementary statement of objections to amalgamate the three investigations into one.

Parties Actavis UK
Actavis UK is a pharmaceutical company, ultimately owned by Allergan plc, a US-based global pharmaceutical group. Actavis UK has now been rebranded as Accord Healthcare. Actavis UK includes the following companies:
• from June 2008 to 31 October 2012–Auden Mckenzie (Pharma Division) Limited
• from 1 November 2012 to 28 May 2015–Auden Mckenzie (Pharma Division) Limited and Auden Mckenzie Holdings Limited
• from 29 May 2015 to 24 June 2016–Auden Mckenzie (Pharma Division) Limited, Auden Mckenzie Holdings Limited, Actavis UK Limited and Allergan plc.

Accord Healthcare and Intas
Accord Healthcare Limited (Accord) acquired Actavis UK in January 2017. Accord is a UK based generic pharmaceutical company. Accord is a wholly-owned subsidiary of Intas Pharmaceuticals Limited.

Intas Pharmaceuticals Limited